2023 article
A second-generation, point-of-care immunoassay provided improved detection of Anaplasma and Ehrlichia antibodies in PCR-positive dogs naturally infected with Anaplasma or Ehrlichia species
Richardson, S. S., Mainville, C. A., Arguello-Marin, A., Whalley, D., Burton, W., Breitschwerdt, E. B., & Qurollo, B. A. (2023, May 9). JOURNAL OF VETERINARY DIAGNOSTIC INVESTIGATION.
author keywords: Anaplasma; dogs; Ehrlichia; immunoassay; point-of-care; serology; tick-borne pathogens
TL;DR:
The second-generation SNAP 4Dx Plus test offered improved serologic detection of Anaplasma and Ehrlichia in naturally infected dogs, and case management decisions might have been different with an immediate anaplasmosis diagnosis, including earlier doxycycline therapy and less hospitalization.
(via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being
(Web of Science)
Source: Web Of Science
Added: May 30, 2023
A validated second-generation SNAP 4Dx Plus (Idexx) incorporates new peptides for improved detection of antibodies against Anaplasma and Ehrlichia tick-borne pathogens in dogs. We compared the first- and second-generation SNAP 4Dx Plus using dogs naturally infected with Anaplasma or Ehrlichia species, or dogs seroreactive by an E. canis indirect fluorescent antibody test (IFAT). The second-generation immunoassay was more sensitive than the first-generation for dogs infected with A. phagocytophilum (51.1% and 29.2%, respectively), A. platys (63.6% and 35.3%, respectively), E. canis (96.2% and 88.3%, respectively), or E. ewingii (73.7% and 70.8%, respectively), and for dogs seroreactive by E. canis IFAT (87.3% and 83.9%, respectively). The second-generation immunoassay detected significantly more Anaplasma- or Ehrlichia-infected dogs that were Anaplasma ( p < 0.001) or Ehrlichia ( p = 0.031) seroreactive, respectively, than did the first-generation test. When Ehrlichia seroreactivity by E. canis IFAT and both immunoassays was compared, significantly more E. canis–infected dogs were seroreactive by E. canis IFAT than the first-generation ( p = 0.006) but not the second-generation ( p = 0.125) immunoassay. Significantly more E. ewingii–infected dogs were seroreactive by the first- ( p = 0.011) and second-generation ( p = 0.049) immunoassays than the E. canis IFAT. Medical records available for 7 dogs that were Anaplasma seroreactive by the second-generation but not the first-generation immunoassay revealed case management decisions that might have been different with an immediate anaplasmosis diagnosis, including earlier doxycycline therapy and less hospitalization. The second-generation SNAP 4Dx Plus test offered improved serologic detection of Anaplasma and Ehrlichia in naturally infected dogs.